Superworth

Integer ITGR

Medical - Devices, Healthcare
$126.55
−0.03%
Market cap
$4.3B
PE
42.5×
10y median 33.6×
Forward PE
n/m
not a meaningful number
Price to sales
2.4×
EV/EBIT
29.7×
Revenue, 12 months
$1.8B
−0% on a year ago
Net margin
5.7%
Free cash flow yield
1.9%

Integer trades at 42.5× trailing earnings, pricier than 78% of the last ten years. Revenue was $1.8B over the last twelve months, down 0% on a year earlier with a 6% net margin.

Charts

Financials

Income statement for ITGR, by quarter
Income statementQ4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
$413.2M+11%$407.8M+8%$427.9M+7%$431.4M+9%$449.5M+9%$437.4M+7%$476.5M+11%$467.7M+8%$472.1M+5%$439.6M+1%$464.1M−3%$449.7M−4%
Cost of revenue$302.9M+10%$299.5M+6%$310.5M+6%$314.8M+8%$332.7M+10%$317.1M+6%$347.3M+12%$341.5M+9%$347.3M+4%$330M+4%$351.2M+1%$348.1M+2%
Gross profit$110.3M+13%$108.3M+12%$117.4M+11%$116.6M+11%$116.8M+6%$120.3M+11%$129.2M+10%$126.2M+8%$124.8M+7%$109.6M−9%$112.9M−13%$101.6M−20%
R&D$13.1M−6%$15.3M−20%$15.6M−8%$11.9M−15%$10.6M−19%$14.2M−7%$14.2M−9%$10.9M−8%$10.1M−5%$16.2M+14%$11.3M−21%$13.5M+24%
SG&A$45.3M+10%$46.4M+11%$46.5M+1%$44.8M+8%$47.5M+5%$51.2M+10%$52.9M+14%$50.5M+13%$57.2M+21%$58.7M+15%$57.7M+9%$54.1M+7%
$43.5M+18%$38.7M+13%$54.5M+31%$58M+19%$57M+31%$49.6M+28%$59.3M+9%$56.4M−3%$55.9M−2%$31.9M−36%$34.5M−42%$28.2M−50%
Interest expense$12.1M−15%$14M−19%$14.6M+27%$14.6M+27%$13.2M+10%$14.8M+6%$9.8M−33%$9.4M−36%$9.3M−30%$9.7M−34%$10.1M+4%$9.7M+4%
Pre-tax income$29.3M+42%$24.8M+55%$40M+34%$43.4M+31%$39.3M+34%−$13M$45.6M+14%$46M+6%$46.8M+19%$20.4M$23.3M−49%$17.5M−62%
$3.2M−10%$4.2M+45%$8.8M+49%$7.1M+41%$6.3M+98%$9.5M+123%$8.6M−3%$6.3M−12%−$1.8M$3.8M−59%−$314K$2.5M−60%
Net income$26.4M+46%$20.5M+57%$31.2M+30%$35.4M+30%$32.7M+24%−$22.5M$37M+18%$39.7M+12%$48.6M+49%$16.5M$23.6M−36%$15M−62%
$0.78+44%$0.59+51%$0.88+24%$0.99+22%$0.90+15%−$0.66$1.04+18%$1.11+12%$1.38+53%$0.48$0.69−34%$0.43−61%
34M+2%35M+4%35.5M+6%35.8M+6%36.2M+7%33.9M−3%35.7M+1%35.6M−1%35.1M−3%34.4M+2%34.1M−4%34.6M−3%

Revenue: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.

Cost of revenue: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.

Gross profit: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.

R&D: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.

SG&A: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.

Operating income: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.

Interest expense: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.

Pre-tax income: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.

Income tax: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.

Net income: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.

EPS, diluted: 11 periods, Q1 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY10: share-days: the 6-month average less the second quarter's. 13 periods, Q4 FY10 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY12 and Q4 FY15: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY16: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Devices nearest Integer's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
ITGRInteger$4.3B42.5×33.6×n/m2.4×−0%5.7%
LIVNLivaNova$4.4B23.7×71.7×n/m3.0×+12%12.8%
TMDXTransMedics$2.3B17.4×55.5×n/m3.5×+26%22.7%
CNMDCONMED$1.4B19.3×52.9×n/m1.0×+2%5.4%
ZBHZimmer Biomet$18.6B23.7×31.2×n/m2.2×+9%9.5%
DXCMDexCom$31.9B33.6×102×30.0×6.4×+16%20.1%
GEHCGE HealthCare Technologies$36B18.3×17.1×15.4×1.7×+7%9.3%
Peer median$11.5B21.5×54.2×22.7×2.6×+11%11.1%

More on Integer

Each number over time

Where it ranks

Its groups

About

Industry
Medical - Devices
Sector
Healthcare

Valuation data, not investment advice. Prices as of .